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Abstract
Background: Generic health-related quality of life measures are often applied to disease groups without assessment of their
psychometric properties. The current work assesses the properties of the Short Form 36-item (SF-36) questionnaire in a British
sample of adolescents and adults with cystic fibrosis (CF). Methods: Two hundred and twenty-three adolescents and adults with
CF completed the SF-36 with a further 185 approached and not responding by non-completion of the questionnaire. The structure
and internal reliability of the instrument was assessed by principal components analysis, Cronbach alpha coefficients and item to
domain correlations. Differences between disease severity groups were assessed by analysis of variance. Results: Factor analysis
of the SF-36 scores broadly confirmed domain structures for the SF-36. Cronbach alpha coefficients were high (range 0.82–0.91)
and item-to-same domain correlations were stronger than item-to-unrelated domain correlations. Examination of differences
between mild, moderate and severe disease states revealed four significant main effects for: physical functioning, role limitation
due to physical functioning, general health perceptions and energy and vitality. The analysis also revealed the presence of
numerous ceiling effects across domains. Conclusions: The domain structure of the SF-36 was demonstrated to be robust.
However, the discriminatory ability of the measure was disappointing. The presence of ceiling effects and the low frequency of
differences between intermediate disease severity groups indicated that the SF-36 was not discriminatory with respect to mild
disease states or progression of illness.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The application of generic health-related quality of
life (HRQoL) measures in disease populations is wide-
spread in both health psychology and the medical
literature. Generic measures are used in health because
they allow comparison between clinical groups and
healthy groups and between different clinical groups.
Because they encompass a wide range of domains
generic measures may also detect quality of life issues
that were not previously thought to be problematic for
a specific disease group. However, testing and validation
of these measures within specific disease groups is
seldom undertaken. It is often assumed that because
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generic HRQoL measures have been validated and tested
on general populations that they are also valid and
reliable amongst specific disease groups. When a more
detailed assessment is conducted, it may be found that
these measures are not suitable for the disease group
under scrutiny w1,2x. If this process of validation is not
undertaken before the measure is applied to a given
group, the outcome scores may be difficult to interpret
and perhaps meaningless.
Previously, the most frequently applied generic meas-
ures in cystic fibrosis (CF) were the Quality of Well
Being (QWB) scale w3–6x and the Nottingham Health
Profile (NHP) w7,8x. Some validation work has been
carried out for the NHP when applied to the CF
population w1x. The authors concluded that the NHP
may not be the most appropriate measure for use in
138 L. Gee et al. / Journal of Cystic Fibrosis 1 (2002) 137–145
adults with CF. Indeed, preference for the SF-36 over
the NHP has been reported w9,10x not least because the
measure provides a less skewed profile than the NHP.
In addition, some doubt has been cast over the validity
of the QWB scale for adults with CF w2x.
The current generic HRQoL measure of choice for
adults with CF is the Short Form 36-item (SF-36) health
status questionnaire w11–16x. The SF-36 has been vali-
dated in Britain amongst general populations w17–19x.
However, despite its increased use amongst the CF
population, the SF-36 has not been independently vali-
dated for use with CF adults. Most importantly, is the
question of whether the SF-36 is able to detect differ-
ences between different levels of disease severity. It is
imperative that researchers are able to accurately eval-
uate their data in the most meaningful way and yet
without this type of validation study this is difficult.
The present work aims to test the structural integrity
and discriminatory ability of the SF-36 as a potential




The SF-36 was completed by 223 adolescents and
adults with CF from two specialist adult CF units in
Manchester and Leeds. This sample represented 103
males and 120 females with a mean age of 25.15 years
(age range 14–52 years).
2.2. Measure
The SF-36 w11–13x was developed from the RAND
corporation health insurance measures w20x and also the
Short Form-20 questionnaire w21x which was included
in the Medical Outcomes Study w22x. The SF-36 repre-
sents a concise yet comprehensive 36-item question-
naire. This makes it ideal for routine use in general
clinical practice as it takes on average only 5 min to
administer. The domains of functioning contained in the
SF-36 include: (1) physical functioning—10 items; (2)
role limitations due to physical functioning—4 items;
(3) mental health—5 items; (4) role limitations due to
emotional problems—3 items; (5) social functioning—
2 items; (6) general health perceptions—5 items; (7)
energy and vitality—4 items and; (8) bodily pain—2
items. In addition, a single item assesses changes in
health over the last 12 months. Scores are summed for
each domain and are then transformed into scores of
between 0 (worst possible health state) to 100 (best
possible health state). The measure was designed to
detect both the presence and absence of problems and
the degree of difficulty experienced, ranging from good
health to poor health.
2.3. Procedure
The SF-36 was distributed to patients at Manchester
and Leeds for return by postal means. Distribution of
the questionnaires coincided with an outpatient clinic
appointment for each patient. Clinical and demographic
data for sex, age, forced expiratory volume in one
second (FEV ) and body mass index (BMI) were1
routinely assessed for all participants on the day they
attended clinic. A pre-paid envelope was included for
all patients to return the questionnaires. Patients were
instructed to return the questionnaires as soon as possible
after the clinic appointment, preferably within a few
days. The date of the outpatient clinic was recorded and
patients were asked to also record the date they com-
pleted the questionnaire. During the study period, if a
non-responding patient had a repeat attendance at clinic
a second questionnaire was sent out and the above
procedure was observed. All questionnaires included in
the present study were returned within a week of
distribution. Clinical status and demographic informa-
tion were also assessed for questionnaire non-responders
and a comparison was made between groups. Data
collection was continuous for a period of 6 months.
2.4. Statistical analysis
Scores on the SF-36 were converted into values that
ranged from 0 to 100. This was in accordance with the
scoring guidelines laid out by Jenkinson et al. w18x.
Descriptive statistics included means, standard deviation,
95% confidence intervals around the mean, floor
(patients scoring between 0 and 5 on the 100-point
scale) and ceiling effects (patients scoring between 95
and 100). Descriptive statistics for clinical, demographic
and HRQoL scores were normally distributed w23x and
are represented as means, standard deviations and 95%
confidence intervals around the mean. Differences
between HRQoL scores for males and females and
between disease severity groups were analysed using
analysis of variance (ANOVA). Due to the number of
multiple comparisons, significance levels were set at
Ps0.01. Post hoc analyses were applied using Tukey’s
Honestly Significant Difference (HSD) test.
The internal structure of the SF-36 was examined
using principal components analysis (PCA), Cronbach
alpha coefficients and item to domain correlational
analysis. Factor analytic procedures were applied to
determine whether domains emerging from the analysis
compared with those outlined in existing literature w18x.
Before conducting the PCA, the data were assessed for
suitability by applying a series of correlation and factor
analysis determinants, which highlighted whether the
data were appropriate for factor analytic procedures.
Appropriateness of the data for analysis using PCA was
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Table 1
Demographic and clinical variables for responders and non-responders
Variables Responders Non-responders
Total population 223 103
Males (n) 103 (46%) 70 (68%)
Females (n) 120 (54%) 33 (32%)
Age
Mean (S.D.) 25.15 (7.1) 24.64 (6.9)
95% CI range 24.2–26.0 23.2–26.0
BMI
Mean (S.D.) 20.88 (2.6) 20.75 (2.9)
95% CI range 20.5–21.2 20.2–21.3
FEV1
Mean (S.D.) 55.63 (23.5) 58.07 (23.8)
95% CI range 52.5–58.7 53.4–62.7
nsnumber in group. Data for non-responders based on 103 non-
responders for whom data were available, not the whole non-respond-
er sample of 185. S.D.sstandard deviation, 95% CIs95% confidence
interval around the mean.
assessed using tests for multicollinearity and singularity.
Multicollinearity and singularity are conditions that exist
in a correlation matrix when the variables are too highly
correlated. In the case of multicollinearity correlated at
above 0.90 and in the case of singularity a perfect
correlation w23x. Multicollinearity normally proves prob-
lematic for factor analysis as it renders inversion of the
matrix during the factor analytic process unstable w23x.
The presence of multicollinearity determined that PCA
would be the most appropriate approach as inversion of
the matrix is not necessary for this type of analysis w23x.
Cronbach alpha coefficients determined the coherence
of items in each domain. Domains are robust when
Cronbach alpha values exceed 0.8 w23x. Item to domain
correlations determined whether the items within a
domain correlated more strongly with other items from
the same domain by comparison to items from other
domains. The mean score for each particular item was
deducted from the total domain mean in order to prevent
‘over fitting’ the item with the domain. Correlation
coefficients for item to same domain should exceed rs
0.4 w24x. The aim of this analysis was to assess whether
items converged with the domain to which they were
proposed to belong whilst discriminating against unre-
lated domains w25x. PCA, Cronbach alpha and item to
domain analysis converged to determine whether the
identified structure of the SF-36 was robust.
Possibly the most important factor to take into account
when assessing domains in a HRQoL questionnaire is
whether they can discriminate between different levels
of disease severity. In order to test the SF-36 in this
respect the overall CF group was divided on the basis
of mild, moderate and severe disease according to their
FEV values w26x. Three groups were arrived at, mild1
disease (FEV )71% predicted), moderate disease (41–1
70% predicted) and severe disease (-40% predicted).
To determine whether the domains of the SF-36 were
able to discriminate between different levels of disease
severity a series of one-way analysis of variance (ANO-
VA) were conducted between groups for each independ-
ent domain. Because of multiple comparisons,
significance levels were again set at 0.01. Where signif-
icant main effects between groups were present, these
were explored using Tukey’s Honestly Significantly
Difference (HSD) post hoc test. In addition, specific
differences highlighted by the Tukey’s HSD were further
explored using the effect size statistic as determined by
Cohen w27x, who described a small effect size as 0.20,
medium effect size y0.50 and a large effect size y
0.80.
Statistical analyses were conducted using SPSS for
windows version 6.0 w28x. Effect sizes for significant
differences were calculated (quoted as ‘d’ in Section 3)
using D-STAT meta-analytic software w29x.
3. Results
3.1. Response rates
One hundred and ninety-three patients from the Man-
chester unit were sent questionnaires. Of these 97 (50%)
were completed and returned following initial contact.
Fifty-one non-responders who had a second clinic
appointment during the trial period were given a further
SF-36. Of the 51 receiving a follow-up contact 13
completed and returned the questionnaires (25%). Of
the original 193 approached 110 (57%) patients returned
completed questionnaires.
In Leeds 215 patients were given questionnaires with
a return rate of 113 (52.5%). Leeds patients were not
followed up for a second time. Complete non-responder
data were not available from Leeds. Data from 20 non-
responders from Leeds were combined with the 83 non-
responders from Manchester to determine whether there
were any differences between the groups in terms of
demographic and clinical variables (displayed in Table
1).
A disparity between the responder population and the
non-responder data was apparent in relation to gender
with 68% of non-responders being male by comparison
to 46% of responders. No significant differences
emerged between responders and non-responders for
age, percentage of predicted FEV or BMI.1
3.2. Descriptive characteristics
Examination of the distribution of scores across the
SF-36 domains suggested a ceiling effect of up to 68%
of respondents achieving scores of 95 or above (Table
2a) across some domains. Floor effects were not
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Table 2b
Clinical, demographic and SF-36 domain means, standard deviations
(S.D.), 95% confidence intervals around the mean (95% CI), and
percentage demonstrating ceiling effects as a function of gender
Mean S.D. 95% CI % Ceiling
effect
Age Male 25.5 6.4 "1.2 nya
Female 24.8 7.6 "1.3 nya
BMI Male 21.2 2.4 "0.4 nya
Female 20.5 2.6 "0.4 nya
FEV1 Male 57.9 23.0 "4.5 nya
Female 53.7 23.8 "4.2 nya
SF-36 domains
Physical Male 82.4 20.7 "4.0 46
functioning Female 71.1 25.4 "4.5 23
Social Male 81.9 22.5 "4.4 46
functioning Female 79.0 24.8 "4.4 45.5
Role limitation Male 75.0 22.5 "7.5 63
physical Female 71.0 39.5 "7.1 58
Role limitation Male 78.0 35.6 "7.0 69
mental Female 76.2 38.1 "6.8 67
Mental health Male 75.5 18.4 "3.6 15
Female 72.1 17.7 "3.2 5
Energy and vitality Male 62.2 21.6 "4.2 7
Female 55.1 23.8 "4.2 5
Pain Male 84.2 19.6 "3.8 49
Female 81.9 22.6 "4.0 45
General health Male 46.8 24.0 "4.3 3
perceptions Female 46.4 23.1 "4.1 0
Changes in health Male 56.3 20.7 "4.0 9
Female 53.9 22.8 "4.1 11
Total SF-36 score Male 77.1 18.6 "3.6 12
Female 72.3 22.1 "3.9 8
Table 2a
SF-36 domain means, standard deviations (S.D.), 95% confidence intervals around the mean (95% CI), and percentage demonstrating floor and
ceiling effects for the total sample
Domain of functioning Mean S.D. 95% CI % Floor % Ceiling
effect effect
Physical functioning 76.31 24.00 "3.16 0.5 34
Social functioning 80.39 23.83 "3.14 0 46
Role limitation physical 72.87 38.39 "5.13 17 60
Role limitation mental 77.03 36.95 "4.87 14 68
Mental health 73.70 18.13 "2.39 0 9.5
Energy and vitality 58.36 23.07 "3.04 1 6
Pain 83.23 21.29 "2.81 .5 47
General health perceptions 43.39 23.71 "3.12 5.5 1
Changes in health 72.78 14.21 "2.73 1 10
Total SF-36 score 55.00 21.87 "2.88 0.40 10
observed to be in effect. Item-by-item examination of
values for skewness and kurtosis indicated that only
four items exceeded acceptability for normal distribu-
tion. These were the mental health item: ‘how much in
the past have you been a very nervous person?’ Physical
functioning items: ‘whether health has limited the par-
ticipant in the activity of bending, kneeling and stoop-
ing’ and ‘whether health has limited the ability to walk
100 yards’. Finally the pain item: ‘during the past two
weeks, how much did pain interfere with your normal
work (including both inside and outside the home?’).
In general, the majority of items and domains were
acceptable in terms of normal distribution of scores.
3.3. Gender differences
Scores across clinical measures, demographics and
SF-36 domains for the responder sample were further
analysed to determine any differences between males
and females. This analysis was approached to examine
whether any salient differences between males and
females existed that may be influential, given the dis-
proportionate non-response from males. Table 2b dis-
plays the descriptive characteristics as a function of
gender and in particular mean averages, standard devi-
ation, 95% confidence intervals around the mean and
ceiling effects.
Factorial ANOVA revealed only one difference
between males and females across clinical measures,
demographics and SF-36 domains (physical functioning
Ps0.001). Tukey’s HSD revealed no intra-group differ-
ences between males and females for disease severity.
Differences were accounted for by within gender differ-
ences (i.e. male moderate and male severe) and differ-
ences between disease severity groups (i.e. female mild
and male severe). There were also no significant inter-
actions across any of the comparisons for gender and
disease severity.
3.4. Internal structure of the SF-36
The determination of the correlation matrix statistic
(not shown in current article) revealed that the matrix
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Table 3
Principal components analysis of the SF-36 data
F1 F2 F3 F4 F5 F6
Eigenvalue 14.17 3.54 1.94 1.59 1.29 1.14
% of variance 41.7 10.4 5.7 4.7 3.8 3.4
Physical functioning
Walking 100 yards 0.82
Walking half a mile 0.81
Climbing one flight of stairs 0.80
Walking more than a mile 0.74
Moderate activities, such as moving a table. Pushing a vacuum 0.68
cleaner, bowling or playing golf
Lifting or carrying groceries 0.65
Climbing several flights of stairs 0.60
Bending, kneeling or stooping 0.57
Vigorous activities such as running, lifting heavy objects, 0.35
participating in strenuous sports
Mental health
How much in the past 2 weeks have you been a happy person? 0.78
How much in the past 2 weeks have you been a very nervous 0.71
person?
How much in the past 2 weeks have you felt so down in the 0.70
dumps that nothing can cheer you up?
How much in the past 2 weeks have you felt calm and peaceful? 0.67
How much in the past 2 weeks have you felt down hearted and 0.67
low?
Energy and vitality
How much in the past 2 weeks did you feel full of life? 0.56
How much in the past 2 weeks did you feel tired? 0.55
How much in the past 2 weeks did you have a lot of energy? 0.54
How much in the past 2 weeks did you feel worn out? 0.52
Social functioning
During the past 2 weeks. How much of the time have your physical 0.47
or emotional problems interfered with your social activities?
During the past 2 weeks, to what extent has your physical health 0.44
or emotional problems interfered with your normal social
activities with family, friends, neighbours or groups?
General health perceptions
My health is excellent 0.79
I am as healthy as anyone I know 0.77
I expect my health to get worse 0.68
In general, would you say that your health is: excellent, very good, 0.67
good, fair, poor?
I seem to get ill a little more easily than other people 0.50
Role limitation due to physical functioning
As a result of your physical health have you: cut down on the 0.80
amount of time you spend on work or other activities?
As a result of your physical health were you: limited in the kind 0.80
of work or other activities that you perform?
As a result of your physical health have you: had difficulty 0.73
performing work or other activities?
As a result of your physical health have you: accomplished less 0.70
than you would like.
Role limitation due to mental health
As a result of any emotional problems you: didn’t do work or 0.73
other activities as carefully?
As a result of any emotional problems have you: cut down on 0.71
the amount of time you spent on work or other activities?
As a result of any emotional problems have you: accomplished 0.64
less than you would like?
Pain
During the past 2 weeks, how much did pain interfere with your 0.81
normal work?
How much bodily pain have you had in the last 2 weeks? 0.73
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Table 4
Item to domain correlations for the SF-36 data
Domain PF RLP RLM SF MH EyV P GHP
Item no. r r r r r r r r
PF1 0.62 0.45 0.21 0.33 0.25 0.56 0.32 0.68a
PF2 0.81 0.54 0.29 0.47 0.29 0.52 0.35 0.58
PF3 0.68 0.42 0.29 0.39 0.29 0.48 0.28 0.49
PF4 0.80 0.54 0.30 0.43 0.26 0.55 0.39 0.59
PF5 0.80 0.53 0.31 0.43 0.24 0.47 0.35 0.49
PF6 0.46 0.33 0.30 0.42a 0.30 0.40a 0.37 0.25
PF7 0.84 0.52 0.33 0.46 0.28 0.52 0.43 0.55
PF8 0.81 0.54 0.34 0.41 0.27 0.46 0.35 0.48
PF9 0.68 0.39 0.25 0.36 0.23 0.37 0.21 0.36
RLP1 0.47 0.78 0.40 0.53 0.38 0.57 0.37 0.36
RLP2 0.56 0.75 0.51 0.58 0.43 0.60 0.46 0.42
RLP3 0.53 0.80 0.39 0.55 0.28 0.54 0.42 0.44
RLP4 0.55 0.73 0.37 0.52 0.32 0.56 0.45 0.40
RLM1 0.35 0.50 0.78 0.54 0.55 0.46 0.40 0.23
RLM2 0.34 0.46 0.72 0.55 0.61 0.51 0.40 0.26
RLM3 0.26 0.31 0.66 0.48 0.48 0.39 0.32 0.20
SF1 0.45 0.55 0.57 0.70 0.58 0.63 0.57 0.39
SF2 0.50 0.60 0.53 0.70 0.58 0.61 0.47 0.42
MH1 0.09 0.17 0.35 0.39 0.52 0.35 0.23 0.10
MH2 0.24 0.32 0.56 0.56 0.71 0.50 0.33 0.24
MH3 0.31 0.36 0.44 0.45 0.59 0.54a 0.25 0.27
MH4 0.32 0.34 0.57 0.58 0.68 0.58 0.36 0.33
MH5 0.33 0.38 0.54 0.50 0.76 0.60 0.27 0.33
EV1 0.56 0.56 0.48 0.60 0.42 0.76 0.45 0.57
EV2 0.58 0.57 0.44 0.57 0.59 0.77 0.44 0.60
EV3 0.52 0.57 0.45 0.57 0.53 0.77 0.47 0.50
EV4 0.54 0.60 0.47 0.62 0.58 0.82 0.50 0.53
P1 0.42 0.48 0.40 0.53 0.34 0.52 0.76 0.38
P2 0.39 0.43 0.41 0.53 0.35 0.45 0.76 0.35
GHP1 0.70a 0.50 0.30 0.47 0.36 0.62 0.31 0.73
GHP2 0.37 0.27 0.08 0.18 0.11 0.32 0.26 0.47
GHP3 0.52 0.35 0.18 0.38 0.30 0.53 0.37 0.74
GHP4 0.33 0.20 0.23 0.22 0.20 0.32 0.23 0.49
GHP4 0.61 0.46 0.25 0.45 0.31 0.62 0.39 0.79
Correlations with own domain are highlighted in bold.
Abbreviations: PF, physical functioning; RLP, role limitation phys-
ical; RLM, role limitation mental; SF, social functioning; MH, mental
health; EV, energy and vitality; P, pain; GHP, general health
perceptions.
Correlations with unrelated domains that are similar to or greatera
than intra item domain correlations.
had fallen prey to either multicollinearity or singularity
(values -0.00001). Visual inspection of the matrix
indicated that this was more likely to be multicollinearity
as no values reached 1 (other than the diagonal). The
Kaiser Meyer Olkin measure of sampling adequacy was
greater than 0.5 (0.9277) whilst the Bartlett test of
sphericity was very highly significant (5728.75, Ps-
0.0000). Accepting the likelihood that the matrix had
fallen prey to multicollinearity, all other a priori tests
for the suitability of factor analysis were robust.
The outcome of the PCA with varimax rotation
revealed the presence of six factors and confirmed the
expected domain structure of the SF-36 (Table 3). This
was with one exception; factor 2 in which three of the
SF-36 domains emerged with all items loading on to
the same factor (social functioning, mental health and
energy and vitality). However, each domain had a
specific pattern of loading within factor 2. Social func-
tioning items ranged in factor loadings from 0.44–0.47,
energy and vitality ranged from 0.52–0.56, whilst men-
tal health ranged from 0.67–0.78. This indicated that
whilst loading onto the same factor, within that factor
items were forming distinct clusters.
Cronbach alpha coefficients were high: physical func-
tioning y0.91, social functioning y0.82, energy and
vitality y0.90, mental health y0.84, role limitations
due to physical functioning y0.89, role limitations due
to mental health y0.85, pain y0.84 and general health
perceptions y0.84, suggesting that the SF-36 had good
internal reliability.
Using a Pearson product moment correlation analysis,
the results are presented in Table 4. The outcome of the
correlation analysis indicated that the vast majority of
items correlated more strongly with their related domain
by comparison to an unrelated domain.
3.5. Discrimination of the SF-36 between different levels
of disease severity
The demographic and clinical data mean domain
scores, standard deviations and confidence intervals for
each group are represented in Table 5.
No significant main effect differences were found
between disease severity groups for social functioning,
mental health, pain, role limitation due to mental health
and changes in health. Significant main effects were
found for physical functioning (Fs17.43, d.f.s2, Ps
-0.000) with specific differences highlighted by the
Tukey’s HSD between mild and moderate disease groups
(ds0.49) and mild and severe disease groups (ds
0.99). Significant main effects were also present for role
limitations due to physical functioning (Fs7.92, d.f.s
2, Ps-0.000) with post hoc differences between mild
and moderate disease (ds0.18) and mild and severe
disease (ds0.67). Energy and vitality yielded a signif-
icant effect (Fs5.21, d.f.s2, Ps0.006) with a specific
difference between mild and severe groups (ds0.56).
A significant main effect was found for general health
perceptions with post hoc analysis indicating significant
differences between all group comparisons (mild and
moderate ds0.49, moderate and severe ds0.63, and
mild and severe ds1.3). Main effects were also present
for total SF-36 scores (Fs5.04, d.f.s2, Ps0.007).
Specific differences for this comparison was for total
SF-36 scores between mild and severe disease (ds
0.39).
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Table 5
Descriptive statistics and mean SF-36 domain scores as a function of disease severity
Total sample Mild Moderate Severe
Total population (n) 223 60 97 66
Male (n) 103 31 45 26
Female (n) 120 29 52 40
Age 25.1 (7.1) 23.5 (6.6) 24.8 (7.3) 27 (6.9)
"0.93 "1.7 "2.9 "1.6
% Predicted FEV1 54.3 (23.5) 86.7 (11.3) 54.2 (9.0) 29.4 (7.2)
"3.1 "2.9 "1.8 "1.7
Body mass index 20.8 (1.9) 22.1 (2.7) 21.0 (2.2) 19.5 (2.1)
"0.35 "2.7 "2.2 "0.05
SF-36 domains
Physical functioning** 76.3 (24) 87.0 (18) 78.3 (21.2) 63.8 (27.2)
"3.2 "6.5 "4.2 "4.2
Role limitation physical** 72.8 (39) 83.3 (32.1) 76.5 (38.2) 58.0 (41.6)
"5.13 "8.2 "7.6 "10
Mental health 73.7 (18) 76.1 (19.4) 72.9 (17.8) 72.5 (17.4)
"2.39 "5.0 "3.5 "4.2
Role limitation mental 77.0 (37) 78.8 (36.8) 74.8 (39.1) 78.6 (33.9)
"4.87 "9.5 "7.8 "8.3
Social functioning 80.3 (24) 84.4 (22.0) 81.3 (23.7) 75.4 (24.9)
"3.14 "5.7 "4.7 "6.1
General health 43.3 (24) 57.6 (21.8) 43.3 (22.6) 30.5 (19.3)
perceptions** "3.12 "4.7 "4.5 "5.2
Energy and vitality** 58.3 (23) 65.1 (23.6) 58.4 (22.3) 52.1 (22.0)
"3.04 "6.1 "4.5 "5.4
Pain 83.2 (21) 87.3 (20.8) 82.0 (21.4) 81.2 (21.2)
"2.81 "5.3 "4.3 "5.2
Changes in health 55.00 (22) 57.5 (23.6) 57.5 (22.2) 49.2 (18.6)
"2.88 "6.1 "4.5 "4.5
Total SF-36 score* 72.78 (14) 80.3 (20.1) 74.9 (20.5) 68.8 (20.2)
"2.73 "5.2 "4.1 "4.9
With the exception of the first three variables, values represent mean ("S.D.) and "95% confidence intervals around the mean.
*Ps-0.01 highly significant; **Ps-0.001 very highly significant, main effect between disease severity groups. nsnumber in group.
4. Discussion
Testing of the SF-36 using PCA broadly confirmed
the anticipated structure as outlined by the existing
literature w18,24x. Additional statistical analysis using
Cronbach alpha analysis and item to domain correlations
confirmed that the internal structure of the SF-36 was
robust. However, the ability of the measure to discrimi-
nate between CF adults with different levels of disease
severity was disappointing with only four out of eight
potential group comparisons attaining significance. The
ANOVAs also highlighted that where significant differ-
ences between disease levels were found, over half of
these differences were between polarised states (i.e.
mild and severe disease states). Where significant dif-
ferences for intermediate levels were found 50% of the
effect sizes for these differences were in the small range
(smaller than 0.50) indicating that the statistically sig-
nificant outcome may have been a function of sample
size. The effect size for the intermediate difference
between mild and moderate disease for physical func-
tioning was small enough to be considered negligible
(ds0.18). A further significant main effect was found
for the total SF-36 score, but additional analysis high-
lighted that this was restricted to a specific difference
between the mild and severe disease highlighting low
discriminatory ability for intermediate disease states.
This outcome suggests that the SF-36 does not discrim-
inate between different levels of disease severity suffi-
ciently enough to detect progressive changes present in
CF. The other issue which may affect the sensitivity of
the SF-36 for the CF population is the presence of
ceiling effects across several domains (physical func-
tioning, social functioning, role limitation due to physi-
cal health, role limitation due to mental health, and
pain).
Ideally, a questionnaire would be further tested for
sensitivity to change in disease status on a longitudinal
basis and the present study reflects a weakness in not
conducting this type of analysis. However, the low
discriminatory ability with 50% of domains failing to
discriminate between different levels of disease severity
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and the presence of ceiling effects (34–68%) across 5
of 8 the domains precluded additional longitudinal
testing of sensitivity for the SF-36 and suggested that
the SF-36 was not able to detect mild restrictions in the
CF population, a finding also recently highlighted in a
German sample w30x. The present work also confirmed
findings that the SF-36 is most discriminatory with
regard to the physical functioning elements of the scale,
but performs poorly on social and mental health aspects
w30x. However, despite these reservations the structure
of the SF-36 amongst the CF population appears to be
robust.
A further potential weakness of the present study was
the level of non-responders, which was 45% of the total
sample that was approached. This kind of response is
not confined to the present study. Overall response rates
for the population sampled were 55%, a figure that was
consistent with the response rate for Walters 1994
epidemiological survey w31x of adults with CF in the
UK (57%). However, a disparity was the high number
of male non-responders by comparison to females and
some missing data for this group. As equal amounts of
males and females did respond, their data were further
examined for any potential differences that may be
salient with regard to the study. No differences of any
significance emerged between males and females for
clinical measures, demographics or SF-36 domains.
Examination of total sample confidence intervals indi-
cated that the overall sample was representative. Fur-
thermore, the vast majority of confidence intervals for
males and females fell within the close ranges for 95%
confidence intervals around each of the means for the
overall sample. With the clear exception of gender, non-
responders were similar to responders in relation to all
other clinical indicators and demographics and therefore
representative of the wider population that was originally
sampled. Furthermore, observed FEV , gender split and1
age in the present study are comparable to other research
into quality of life w30,32x. However, it cannot be ruled
out entirely that there may be some bias introduced into
research by the presence of non-responders and the
present study is not unusual in this respect.
It appears to be the case that no generic questionnaire
is entirely appropriate for adults with CF w33–35x, and
that routine examination of HRQoL issues is best con-
fined to disease-specific measurement w35x. A correctly
developed disease-specific measure has the advantage
of containing items that are meaningful to the patient
group. Because of this, it is more likely that these
measures will be sensitive to changes in health or more
readily able to discriminate between differences in dis-
ease severity w36x than generic measures. This brings
into question the meaningfulness of using generic ques-
tionnaires and the value of the data gleaned from them.
Determining which of the effects are genuine and which
are artefacts of the measure may only be possible by
comparing the results from a generic measure with those
of a disease-specific questionnaire. However, even with-
in this framework full validation is not possible as each
generic measure contains domains that are not related
to the disease in question and would, therefore, not
appear in a disease-specific measure. Because of this
generic and disease-specific measures may not be direct-
ly comparable. This raises the issue as to whether the
use of generic measures amongst the CF population, or
for that matter any medical population that has its own
idiosyncratic problems, is to some degree spurious. The
rationale for comparisons between different disease pop-
ulations or between disease groups and a general popu-
lation must be thoroughly addressed. If there are no
clinical reasons other than academic curiosity, then the
collection of such data may prove to be an unnecessary
intrusion for the patient.
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